Business
Sonoma Pharmaceuticals develops and markets stabilized hypochlorous-acid products for wound care, dermatology, eye care, oral care and animal health.
Sonoma's antimicrobial-care revenue accelerated and losses narrowed, but cash burn worsened and a flagged statistical screen keeps the recovery speculative.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 36.7%OK
- Profitability — The net loss narrowed from $3.457M to $3.175MOK
- Cash flow — Free cash flow remained negative, with the outflow widening from $168K to $4.125MWatch
- Margins — Operating margin expanded 1337 bps to -12.60%OK
- Accounting — Growth with weak cash conversion and a flagged screenWatch
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2026, as Sonoma Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Human Care$17.7M
- Animal Care$1.8M
Leadership changes
From Sonoma Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Vanessa Jacoby · director · appointmenteff. 2026-01-28
- Jay Birnbaum · Directors · departureeff. 2026-01-28
- Bruce Thornton · Chief Operating Officer · departureeff. 2025-12-02
Latest filings
- 8-K · Company announcement2026-08-19
- 10-Q · Quarterly report2026-08-06
- DEF 14A · Annual proxy (pay & governance)2026-07-28
- 8-K · Company announcement2026-06-18
- 10-K · Annual report2026-06-16
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Sonoma Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.